Buscar
Mostrando ítems 31-40 de 80
Treatment With Dasatinib Or Nilotinib In Chronic Myeloid Leukemia Patients Who Failed To Respond To Two Previously Administered Tyrosine Kinase - Inhibitors A Single Center Experience
(HOSPITAL CLINICAS, UNIV SAO PAULOSAO PAULO, 2015)
Estudio de los mecanismos de resistencia asociados al tratamiento con inhibidores de tirosina kinasas en leucemias philadelphia positivas
(Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica, 2015)
Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
(PERGAMON-ELSEVIER SCIENCE LTD, 2009)
Chronic myeloid leukemia (CML) is a rare disease in childhood which is almost exclusively associated with bcr-abl p210 (M-bcr) rearrangements. It has been suggested that co-expression of p 190 and p210 may be a pathway of ...
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
(Amer Soc Clinical OncologyAlexandriaEUA, 2010)
Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenous leukemia
(2007)
RT-PCR studies in 93 patients with chronic myelogenous leukemia from the Mexican West were done in order to know the proportion of b2a2 and b3a2 BCR/ABL1 transcripts. Forty-five patients showed the b3a2 transcript (48%), ...
Prevalence of the BCR/ABL1 transcripts in Mexican patients with chronic myelogenous leukemia
(2007)
RT-PCR studies in 93 patients with chronic myelogenous leukemia from the Mexican West were done in order to know the proportion of b2a2 and b3a2 BCR/ABL1 transcripts. Forty-five patients showed the b3a2 transcript (48%), ...